Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Links Smoking in College to Other Risky Student Behaviors

March 1, 1998
Publication
Article
OncologyONCOLOGY Vol 12 No 3
Volume 12
Issue 3

College students who smoke not only are endangering their health but also are likely to have adopted other risky behaviors. A new study by researchers at Dana-Farber Cancer Institute and the Harvard School of Public Health has found that college students who smoke are more likely to use marijuana and other illegal drugs, to be sexually promiscuous, and to be uninvolved in sports and athletic activities.

College students who smoke not only are endangering their health but also are likely to have adopted other risky behaviors. A new study by researchers at Dana-Farber Cancer Institute and the Harvard School of Public Health has found that college students who smoke are more likely to use marijuana and other illegal drugs, to be sexually promiscuous, and to be uninvolved in sports and athletic activities.

The study, published in the January issue of the American Journal of Public Health, suggests that encouraging students to participate in more productive aspects of campus life might have the additional benefit of deterring them from smoking.

“College presents an opportunity to reach smokers while society still has ‘institutional’ access to them,” says study coauthor Karen Emmons, PhD, of Dana-Farber and the Harvard School of Public Health. “Smoking should serve as a warning sign to resident assistants and other college counselors that these students need to be drawn more fully into college life.”

Large Number of Students Surveyed
The study is based on a survey of more than 17,000 students at 140 four-year colleges across the country. Students were asked to complete a questionnaire about their use of alcohol, cigarettes, and illicit drugs and to provide information on their living arrangements, lifestyle, and academic performance.

Analysis of the survey showed that 22% of the students had smoked within the previous 30 days and 25% were former smokers—meaning that almost half of all students surveyed had smoked at some point in their lifetime. Among the current smokers, 34% smoked at least half a pack a day and 14% smoked a pack or more a day. College smoking was found to be linked with a variety of behaviors that are either physically or psychologically unhealthy. Students who engaged in binge-drinking prior to college, for example, were almost twice as likely to smoke in college than students who did not binge-drink. Students who smoked were also more likely to use marijuana and to have had multiple sex partners during the previous month.

Lifestyle Choices Influence Smoking
Lifestyle choices were shown to exert a powerful influence on student smoking. Researchers found that smokers were less likely to participate in intercollegiate athletics (a trend that held for male students only) and tended to be less involved in community service, religion, arts, and productive activities and to be more involved in leisure activities. Membership in a fraternity or sorority also increased the likelihood of being a smoker, as did frequent attendance at parties.

One intriguing finding of the study was that risk-taking behavior was an even more powerful predictor of smoking in female students than in their male counterparts.

“Clearly, there is a strong association between students’ lifestyle and the decision of whether or not to smoke,” Emmons says. “The link between high school binge drinking and college smoking may indicate that smoking among college students is part of a risk-taking lifestyle initiated well before college.”

Encouraging Healthy Lifestyles
Fortunately, colleges and universities have at their disposal a variety of options for encouraging healthy lifestyles among students, Emmons notes, from policies banning smoking in university buildings to programs encouraging involvement in the arts, sports, and community service. “By instituting strong policies regarding smoking, universities can establish norms about what values and activities they consider acceptable and what they don’t,” she says.

Part of the challenge facing universities in formulating such policies is that student behavior so often seems contradictory. Participation in intercollegiate sports, for instance, seems to discourage smoking but has been associated with binge-drinking. “It’s important for colleges to take a multifaceted approach to these problems,” Emmons says. “They need to give students the confidence that if they can change one risk behavior, they can change another.”

The difficulty of making and enforcing such policies should not deter colleges from the effort, she remarks. “College is a transitional time in young people’s lives. It’s a time to try and figure out what your lifestyle is going to be like in the future. Colleges and universities have a responsibility to help shape those decisions in healthy directions.”

Emmons’ coauthors on the study were Henry Wechsler, PhD, and Melissa Abraham of the Harvard School of Public Health, and George Dowdall, PhD, of St. Joseph’s University in Philadelphia.

Articles in this issue

Preclinical Studies Using the Intratumoral Aromatase Model for Postmenopausal Breast Cancer
Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer
Status of Antiestrogen Breast Cancer Prevention Trials
Antiestrogen Therapy: Uncertainties and Risk Assessment
Adjuvant Trials of Toremifene vs Tamoxifen: The European Experience
Pivotal Trials of Letrozole: A New Aromatase Inhibitor
Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer
SGO Clinical Practice Guidelines: Introductory Remarks
Scientists Define New Role for Cell Signaling Pathway
Coalition Formed to Further Clinical Cancer Research
New Genetic Defect Signals Need for Aggressive Leukemia Treatment
Investigators Involved in Toremifene Studies Call It a Potentially Safer Antiestrogen
New Kind of Vaccine Aimed at Disseminated Melanoma
Steroid Improves Cancer-Fighting Ability of Vitamin D Analog
Study Links Smoking in College to Other Risky Student Behaviors
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Advertisement

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.


The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Related Content
Advertisement

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.


The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.